Linperlisib
Sponsors
Shanghai Yingli Pharmaceutical Co. Ltd., Shanghai Yingli Pharmaceutical Co. Ltd., Ruijin Hospital, Institute of Hematology & Blood Diseases Hospital, China, Shanghai YingLi Pharmaceutical Co. Ltd., Beijing Tongren Hospital
Conditions
Acquired Pure Red Cell AplasiaAutoimmune Hemolytic AnemiaFailure of Two Rounds of TreatmentFocus on the Lymphoma Including B/T-cell LymphomaIndolent B-cell LymphomaNatural Killer/T-Cell Lymphoma, Nasal and Nasal-TypePeripheral T Cell LymphomaPeripheral T Cells Lymphoma (PTCL)
Phase 1
A Umbrella Study in R/R PTCL Guided by Molecular Subtypes
RecruitingNCT05559008
Start: 2022-09-30End: 2026-01-26Target: 116Updated: 2022-11-09
PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy
TerminatedNCT05676697
Start: 2023-01-13End: 2024-02-06Updated: 2026-02-11
Efficacy and Safety of PI3K Inhibitors in Relapsed/Refractory Large Granular T Lymphocytic Leukemia
CompletedNCT05676710
Start: 2023-02-10End: 2024-02-14Updated: 2024-05-29
Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma
RecruitingNCT06376721
Start: 2024-04-14End: 2027-10-31Target: 43Updated: 2024-04-19
Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma
Not yet recruitingNCT07139353
Start: 2025-09-15End: 2029-09-01Target: 54Updated: 2025-08-24
Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma
Not yet recruitingNCT07209163
Start: 2025-10-31End: 2027-03-31Target: 48Updated: 2025-10-06
Phase 2
A Single-arm, Phase II Study to Evaluate the Efficacy and Safety of Linperlisib (YY-20394) Monotherapy in Patients with Relapsed or Refractory Peripheral T/NK Cell or Cutaneous T Cell Lymphoma
CompletedCTIS2022-501431-16-00
Start: 2023-01-17End: 2024-06-18Target: 16Updated: 2024-04-11
Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia
RecruitingNCT06224257
Start: 2023-12-03End: 2026-01-31Target: 41Updated: 2025-08-05
Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL
RecruitingNCT06489808
Start: 2024-05-28End: 2027-05-31Target: 89Updated: 2024-07-08
A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma
Not yet recruitingNCT06548347
Start: 2024-09-10End: 2029-09-30Target: 606Updated: 2024-08-12
Linperlisib in the Treatment of aPRCA
Not yet recruitingNCT07031115
Start: 2025-09-01End: 2026-12-31Target: 15Updated: 2025-06-22